We examined the effects of an engineered probiotic, Saccharomyces boulardii, on colitis-related cancer in a specific mouse model. Over 18 weeks, mice received either the modified probiotic, standard S. boulardii, or a placebo.
While the engineered strain showed promise in binding to inflamed tissue, it ultimately did not significantly lower cancer development linked to colitis. Our findings suggest that more enhancements are necessary to fully unlock its potential against tumorigenesis.